Abstract
SHS investigation development is considered from the geographical and historical viewpoint. 3 stages are described. Within Stage 1 the work was carried out in the Department of the Institute of Chemical Physics in Chernogolovka where the scientific discovery had been made. At Stage 2 the interest to SHS arose in different cities and towns of the former USSR. Within Stage 3 SHS entered the international scene. Now SHS processes and products are being studied in more than 50 countries.
Abstract
Thrombosis and thrombocytopenia are common in malignancy due to microangiopathic disorders (thrombocytopenic purpura, immune disorder, immune thrombocytopenic purpura, and heparin-induced thrombocytopenia), chemotherapy side effect, or direct cancer effect. Recurrent VTE (while on anticoagulation) is also common, risk factors include metastasis, young age, and short interval between cancer diagnosis and VTE. VTE remains a major challenge among those with renal impairment. Incidental VTE is an unexpected thrombosis detected in a patient undergoing imaging study for other indications. Incidental VTE has been attributed to malignancy or chemotherapy side effects. Philadelphia chromosome-negative Myeloproliferative Disorders (Polycythemia Vera (PV), Essential thrombocytosis (ET), and Primary Myelofibrosis (PMF) has been implicated with high risk for both venous and arterial thromboembolism. Venous thromboembolism (VTE) has been increasingly associated with hematological malignancy as well.
Keywords:
Bone marrow transplant and VTE, Cancer-associated thrombosis, Chemotherapy, Incidental VTE in cancer, Recurrent VTE, Thrombocytopenia, Thrombosis, Thrombosis in malignancy, VTE and thrombocytopenia, VTE in myeloproliferative disorder, VTE in renal impairment.
Recommended Chapters
We recommend
Authors:Bentham Science Books